If you have been reading about prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
A 2024 systematic review of human and animal observational studies concluded that MNPs are "suspected" to be harmful to human reproductive, respiratory, and digestive health. The World Health Organization has acknowledged growing concerns, but note that standardized measurement methods and risks have not been established, calling for further research and improved management of plastic throughout its life-cycle.
==== Tissue engineering ==== Cells are very sensitive to nanotopographical features, so optimization of surfaces in tissue engineering has pushed towards implantation. Under appropriate conditions, a carefully crafted 3-dimensional scaffold is used to direct cell seeds toward artificial organ growth. The 3-D scaffold incorporates various nanoscale factors that control the environment for optimal and appropriate functionality. The scaffold is an analog of the in vivo extracellular matrix in vitro, allowing for successful artificial organ growth by providing the necessary, complex biological factors in vitro.
Not only paints and inks, but other industries such as pharmaceutical, construction, and cosmetics, especially hair styling aids and facial detoxifying masks increasingly favor bentonite and attapulgite clays over other rheology modifiers, dispersion aids, opacifying fillers, antifoam, and numerous niche uses which exploit the numerous inherent qualities which have drawn artisans to this material. Clays are sustainably sourced and do not involve any egregious environmental damage, which were among the cheapest bulk materials until recently, when the pricing went up steadily, following the upsurge in its use pattern. Cellulosics - CMC, HMC, HPMC, and others, are chemically substituted cellulose macromolecules. The hydroxyl groups are substituted by other functional groups, such as methyl or propyl. The amount of substitution and molecular weight determine viscosity of the solution, assuming concentration stays the same; adding more also increases viscosity. Sulfonates - Sodium or calcium salts, good water retention, versatile, and highly efficient. Gums - guar, xanthan, cellulose, locust bean, and acacia are the main ones. Saccharides - carrageenan, pullulan, konjac, and alginate, sometimes called hydrocolloids, these thickeners are extremely versatile and specific in function—each has a series of grades or types which behave differently, for example kappa carrageenan will form strong gels (potassium activated) but iota carrageenan will not form gels and only thickens. Proteins - Casein, collagen, and sometimes albumin.
Sources: en.wikipedia.org
== LLFP radioactivity compared == In total, the other six LLFPs, in thermal reactor spent fuel, initially release only a bit more than 10% as much energy per unit time as Tc-99 for U-235 fission, or 25% as much for 65% U-235+35% Pu-239. About 1000 years after fuel use, radioactivity from the medium-lived fission products Cs-137 and Sr-90 drops below the level of radioactivity from Tc-99 or LLFPs in general. (Actinides, if not removed, will be emitting more radioactivity than either at this point.) By about 1 million years, Tc-99 radioactivity will have declined below that of Zr-93, though immobility of the latter means it is probably still a lesser hazard. By about 3 million years, Zr-93 decay energy will have declined below that of I-129. Nuclear transmutation is under consideration as a disposal method, primarily for Tc-99 and I-129 as these both represent the greatest biohazards and have the greatest neutron capture cross sections, although transmutation is still slow compared to fission of actinides in a reactor. Transmutation has also been considered for Cs-135, but is almost certainly not worthwhile for the other LLFPs. Given that stable caesium-133 is also produced in nuclear fission and both it and its neutron activation product 134Cs are neutron poisons, transmutation of 135Cs might necessitate isotope separation. 99Tc is particularly attractive for transmutation not only due to the undesirable properties of the product to be destroyed and the relatively high neutron absorption cross section but also because 100Tc rapidly beta decays to stable 100Ru.
Trump declared that the United States "[does] not need the help of anyone" regarding the war. In the morning of 17 March, senior Iranian officials, including Ali Larijani and Basij chief Gholamreza Soleimani were targeted by Israeli airstrikes. Both their deaths were later confirmed by Iranian state media. In response, Iran launched a missile barrage that killed two Israeli civilians in Ramat Gan. The same day, Israel launched a ground invasion of southern Lebanon.
== Preservation and conditioning == The natural fibers of leather break down with the passage of time. Acidic leathers are particularly vulnerable to red rot, which causes powdering of the surface and a change in consistency. Damage from red rot is aggravated by high temperatures and relative humidities. Although it is chemically irreversible, treatments can add handling strength and prevent disintegration of red rotted leather. Exposure to long periods of low relative humidities (below 40%) can cause leather to become desiccated, irreversibly changing the fibrous structure of the leather. Chemical damage can also occur from exposure to environmental factors, including ultraviolet light, ozone, acid from sulfurous and nitrous pollutants in the air, or through a chemical action following any treatment with tallow or oil compounds. Both oxidation and chemical damage occur faster at higher temperatures. There are few methods to maintain and clean leather goods properly such as using damp cloth and avoid using a wet cloth or soaking the leather in water. Various treatments are available such as conditioners. Saddle soap is used for cleaning, conditioning, and softening leather. Leather shoes are widely conditioned with shoe polish.
=== Anaesthesia === A common regimen for general anesthesia for the house mouse is ketamine (in the dose of 100 mg per kg body weight) plus xylazine (in the dose of 5–10 mg per kg), injected by the intraperitoneal route. It has a duration of effect of about 30 minutes.
Sources: en.wikipedia.org
== Research directions == Recently, a large body of scientific research deals with the background of autoimmune disease, the cause of many rheumatic disorders. Also, the field of osteoimmunology has emerged to further examine the interactions between the immune system, joints, and bones. Epidemiological studies and medication trials are also being conducted. The Rheumatology Research Foundation is the largest private funding source of rheumatology research and training in the United States.
== Province-wide expansion and termination == In May 2022, Alberta Health Services signed a 15-year contract valued at approximately $4.8 billion with DynaLIFE to provide community laboratory services across Alberta. Province-wide service delivery began in December 2022. In August 2023, eight months after the transition, Alberta Health Services terminated the agreement at the request of DynaLIFE's owners and transferred the company's Alberta operations to Alberta Precision Laboratories. A 2025 examination by the Auditor General of Alberta found breakdowns in governance, due diligence, risk assessment and financial analysis. The examination found that the Minister and Department of Health expected Alberta Health Services to proceed despite concerns about projected savings, pressures associated with the COVID-19 pandemic and the presence of only one remaining bidder. Neither Alberta Health Services nor the Department of Health completed the required business case, and Alberta Health Services did not adequately evaluate the assumptions underlying DynaLIFE's financial proposal. The examination also found that Alberta Health Services and DynaLIFE proceeded with the transition while essential requirements, including laboratory information-system readiness, remained incomplete. A lack of shared operational planning contributed to increased wait times and diagnostic errors, and an above-average number of pathology-result errors compromised patients. The Auditor General attributed $77 million in non-value-added costs to the unsuccessful outsourcing initiative.
Prince Alexander Ferdinand Albrecht Achilles Wilhelm Joseph Viktor Carl Feodor of Prussia (26 December 1912 – 12 June 1985), who married Armgard Weygand on 19 December 1938. They had one son, Prince Stephan Alexander Dieter Friedrich of Prussia (1939–1993); he had one daughter, Princess Stephanie Victoria-Louise of Prussia (born 1966).
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.